Correction to: Leukemia (2013) 27, 718–721; doi:10.1038/leu.2012.206
Since the publication of this article, the authors have noticed an omission in the acknowledgements section, namely that ‘Cancer Research UK’ was not included.
The corrected acknowledgements appear here.
Acknowledgements
We thank Christopher Baum and Olga Kustikova for their help with the ligation-mediated PCR, and Martin Stanulla and Martin Schrappe for the provision of sample L4951. SB is funded by a Medical Research Council (MRC) Clinical Research Training Fellowship. The IVIS Spectrum was funded by a grant from the Wellcome Trust, grant 087961. Additional funding came from a programme grant by CR-UK (grant number C27943/A12788), project funding from Leukaemia Lymphoma Research (LLR) and core infrastructure support from the North of England Children's Cancer Research Fund (NECCR).
Additional information
The authors would like to apologize for any inconvenience this may have caused.
The online version of the original article can be found at 10.1038/leu.2012.206
Rights and permissions
About this article
Cite this article
Bomken, S., Buechler, L., Rehe, K. et al. Erratum: Lentiviral marking of patient-derived acute lymphoblastic leukaemic cells allows in vivo tracking of disease progression. Leukemia 27, 1792 (2013). https://doi.org/10.1038/leu.2013.113
Published:
Issue Date:
DOI: https://doi.org/10.1038/leu.2013.113
